Profound Medical logo

PRN - Profound Medical Share Price

C$17.11 0.8  4.7%

Last Trade - 25/05/20

Sector
Healthcare
Size
Small Cap
Market Cap £154.4m
Enterprise Value £119.5m
Revenue £3.30m
Position in Universe 416th / 2657
Bullish
Bearish
Unlock PRN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Profound Medical Corp revenues increased 6% to C$1.6M. Net loss increased 23% to C$3.6M. Revenues reflect Germany segment increase from C$526K to C$1.1M. Higher net loss reflects Canada segment loss increase from C$1.5M to C$5.5M, Germany segment loss increase of 62% to C$370K. Basic Earnings per Share excluding Extraordinary Items increased from -C$0.27 to -C$0.25.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PRN Revenue Unlock PRN Revenue

Net Income

PRN Net Income Unlock PRN Revenue

Normalised EPS

PRN Normalised EPS Unlock PRN Revenue

PE Ratio Range

PRN PE Ratio Range Unlock PRN Revenue

Dividend Yield Range

PRN Dividend Yield Range Unlock PRN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PRN EPS Forecasts Unlock PRN Revenue
Profile Summary

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company’s products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated July 16, 2014
Public Since September 24, 2014
No. of Shareholders: n/a
No. of Employees: 75
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Toronto Stock Exchange
Shares in Issue 16,079,327
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PRN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PRN
Upcoming Events for PRN
Similar to PRN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.